SANA vs. RARE
Compare and contrast key facts about Sana Biotechnology, Inc. (SANA) and Ultragenyx Pharmaceutical Inc. (RARE).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: SANA or RARE.
Key characteristics
| SANA | RARE | |
|---|---|---|
| YTD Return | -26.35% | 5.31% |
| 1Y Return | -9.08% | 44.09% |
| 3Y Return (Ann) | -48.15% | -14.66% |
| Sharpe Ratio | -0.11 | 0.92 |
| Sortino Ratio | 0.54 | 1.57 |
| Omega Ratio | 1.06 | 1.19 |
| Calmar Ratio | -0.11 | 0.48 |
| Martin Ratio | -0.26 | 2.88 |
| Ulcer Index | 39.33% | 13.51% |
| Daily Std Dev | 93.86% | 42.27% |
| Max Drawdown | -93.56% | -82.11% |
| Current Drawdown | -93.09% | -71.61% |
Fundamentals
| SANA | RARE | |
|---|---|---|
| Market Cap | $670.92M | $4.65B |
| EPS | -$1.40 | -$6.34 |
| Total Revenue (TTM) | $0.00 | $522.75M |
| Gross Profit (TTM) | -$15.18M | $433.15M |
| EBITDA (TTM) | -$219.77M | -$499.22M |
Correlation
The correlation between SANA and RARE is 0.43, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Performance
SANA vs. RARE - Performance Comparison
In the year-to-date period, SANA achieves a -26.35% return, which is significantly lower than RARE's 5.31% return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
SANA vs. RARE - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Sana Biotechnology, Inc. (SANA) and Ultragenyx Pharmaceutical Inc. (RARE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
SANA vs. RARE - Dividend Comparison
Neither SANA nor RARE has paid dividends to shareholders.
Drawdowns
SANA vs. RARE - Drawdown Comparison
The maximum SANA drawdown since its inception was -93.56%, which is greater than RARE's maximum drawdown of -82.11%. Use the drawdown chart below to compare losses from any high point for SANA and RARE. For additional features, visit the drawdowns tool.
Volatility
SANA vs. RARE - Volatility Comparison
Sana Biotechnology, Inc. (SANA) has a higher volatility of 20.46% compared to Ultragenyx Pharmaceutical Inc. (RARE) at 7.38%. This indicates that SANA's price experiences larger fluctuations and is considered to be riskier than RARE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
SANA vs. RARE - Financials Comparison
This section allows you to compare key financial metrics between Sana Biotechnology, Inc. and Ultragenyx Pharmaceutical Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities